natgillin/translations-raw huggingface dataset:
An engineered antibody of claim 20 for use according to claim 20, wherein the effect on tumor growth is independent on the indirect anti-tumor effect of said antibody caused by its angiogenesis blocking effect. 
Genetički izmijenjeno protutijelo prema zahtjevu 20 za uporabu prema zahtjevu 20, naznačeno time da je učinak na rast tumora neovisan o neizravnom anti-tumorskom učinku navedenog protutijela koji je uzrokovan sa njegovim učinkom blokiranja angiogeneze.
stands for hydrogen atom, straight or branched C1-4 alkyl group, or a phenyl-, benzyl-, thienyl-, or furyl group, optionally substituted with methylenedioxy group, or with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxyl group, trifluoromethyl group, cyano group, or halogen atom, or a 5- or 6-membered heterocyclic ring containing one or two or three or four nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom, and one sulphur atom, optionally substituted with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, or halogen atom; stands for cyano group, aminocarbonyl group, -CO-O-(C1-4 straight or branched alkyl) group or carboxyl group; 
predstavlja atom vodika, nerazgranatu ili razgranatu C1-4 alkilnu skupinu, ili fenilnu, benzilnu, tienilnu ili furilnu skupinu, izborno supstituiranu s metilendioksi skupinom ili s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina, hidroksilnih skupina, trifluormetilnih skupina, cijano skupina ili atoma halogena, ili ili 6-eročlani heterociklički prsten, koji sadrži jedan ili dva ili tri ili četiri atoma dušika, ili jedan atom dušika i jedan atom kisika ili jedan atom dušika, i jedan atom sumpora, izborno supstituiran s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina ili atoma halogena; predstavlja cijano skupinu, aminokarbonilnu skupinu, -CO-O-(C1-4 nerazgranati ili razgranati alkil) skupinu ili karboksilnu skupinu;
The pharmaceutical composition according to any of claims 1 to 3, wherein the at least one peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu peptid uključuje nepeptidne veze.
In one embodiment the present invention relates to an oral pharmaceutical dosage form comprising at least buprenorphine or a pharmaceutically acceptable salt thereof with a dosage form releasing buprenorphine or said pharmaceutically acceptable salt thereof instantly upon or oral, preferably sublingual, application of the dosage form. 
HR P20130344 T1 PATENTNI ZAHTJEVI Oralni farmaceutski dozirni oblik koji sadrži barem buprenorfin ili njegovu farmaceutski prihvatljivu sol gdje dozirni oblik oslobađa u biti sav buprenorfin ili njegovu farmaceutski prihvatljivu sol za manje od 2 minute nakon oralne, poželjno sublingvalne, primjene dozirnog oblika.
A process for preparing, starting from a slag material, a filler (32) for use in construction materials which contain a hydraulic or bituminous binding agent, characterised in that use is made of a slag material containing Y-dicalcium silicate; and in that the process comprises the steps of: 
Postupak pripreme, počevši od troske, punila (32) za uporabu u građevnim materijalima koji sadrže hidraulične ili bituminozne vezne tvari, naznačen time što se koristi troska koja sadrži Y-dikalcijev silikat; i time što postupak obuhvaća korake:
Excipients according to the invention are preferably selected from the group consisting of diluents, disintegrants, carriers, binders, flow regulators, lubricants and solvents. 
Čvrsta formulacija prema patentnom zahtjevu 2, naznačena time, da se jedno ili više pomoćnih sredstva odabire iz skupine koja se sastoji od razrjeđivača, dezintegratora, nosača, veziva, regulatora protočnosti, maziva 1 otapala.
conversion of 4 or 4 *, particularly under conditions of a Sharpless oxidation, to create compound F or F *, respectively; 
£ (d) prevođenje spoja 4 ili 4*, naročito pod uvjetima oksidacije Sharplessove, kako bi se dobio spoj F ili spoj 10
The system according to claim 9, wherein the LBAS Db is connected to a probe for monitoring the traffic between a mobile switch centre (MSC) and a visitor location register (VLR) residing within the network holding current details about subscribers and equipment used. 
Sustav prema zahtjevu 9, naznačen time da LBAS Db (25) je povezan sa sondom (20) za nadgledanje prometa između mobilnog preklopnog centra (MSC) i registra lokacije posjetitelja (VLR) koji se nalazi unutar mreže i sadrži aktualne podatke o pretplatnicima i opremi koja se koristi.
A solid system for modified release in accordance with claim 7, wherein the enteric coating comprises cellulose derivatives, preferably selected from cellulose acetate phtalate, cellulose acetate propionate, acrylic or methacrylic acid derivatives, shellac, modified starched, alginates, propolis and mixtures thereof. 
Čvrsti sustav za modificirano oslobađanje u skladu s patentnim zahtjevom 7, naznačen time što gastrorezistentni omotač sadrži derivate celuloze, poželjno izabrane od celuloza acetat ftalata, celuloza acetat propionata, derivata akrilne ili metakrilne kiseline, šelaka, modificiranog škroba, alginata, propolisa i njihovih smjesa.
D-methadone for use according to claim 1, wherein the NMDA receptor is capable of biological action, and wherein the substance is effective to block the biological action of the NMDA receptor. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što je NMDA receptor sposoban za biološko djelovanje, te pri čemu je tvar učinkovita za blokiranje biološkog djelovanja NMDA receptora.
The first end 41 of the spacer 40 may be relatively close to the horizontal hinge axis H connecting the frame 10 to the deck 5 of the vessel 4 . 
Plovilo (4) sukladno Zahtjevu 4, pri čemu je prvi kraj (41) odstojnika (40) povezan s okvirom (10) u blizini osi
Spraying said aqueous suspension on granules of a fumaric acid ester and/or a binder for a period of time sufficient to obtain a uniform coating thereon; 
HR P20130480 T1 b) raspršivanje spomenute vodene otopine na granule estera fumarne kiseline u vremenskom razdoblju dovoljnom za dobivanje jednolične obloge na njima;
one or more pharmaceutically acceptable excipients. 
(c) jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
or an anhydride, solvate or pharmaceutically acceptable salt thereof. 
(OL O ili anhidrid, solvat ili njihova farmaceutski prihvatljiva sol.
A is selected from the group consisting of phenyl, pyridyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, lower alkyl, lower cycloalkyl, or halogen; 
A je izabran iz grupe koju čine fenil, piridil, pirazolil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabrane iz grupe koju čine OH, C,4 alkil, C3.4 cikloalkil, ili halogen;
The binding molecule of any one of claims 20 to 22, wherein said antibody includes Fab fragments, F(ab')2, Fv, scFv fragments, single domain antibodies, nanobodies, diabodies, DART antibodies, single chain diabodies, tandem diabodies, minibodies, Fc DART antibodies, IgG DART antibodies, and multibodies. 
Vezujuća molekula prema bilo kojem od patentnih zahtjeva 21 do 23, naznačena time što navedeno protutijelo sadrži Fab fragmente, F(ab'),, Fv, scFv fragmente, jedno domenska protutijela, nanotijela, diatijela, DART protutijela, jednolančana diatijela, tandem diatijela, minitijela, Fc DART protutijela, I&G DART protutijela, i multitijela.
Clause 12. The method of Clause 11, wherein the Mtb72f is a polypeptide consisting of residues 1 and 4-725 of SEQ NO:4 optionally with a His tag inserted following the initial Met residue. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 14-725 iz SEQ ID NO<4, izborno s ubačenim biljegom His iza početnog ostatka Met.
A process for validating a batch of a pharmaceutical product containing N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof and a pharmaceutically acceptable carrier for distribution comprising 
Postupak za validaciju šarže farmaceutskog produkta koji sadrži spoj N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid ili njegovu sol, te farmaceutski prihvatljiv nosilac za distribuciju, naznačen time, da obuhvaća:
the light conduction device is the light conduction cylinder having a front end being vertically fixed; the convex-concave lens group coupled to the light conduction cylinder is disposed in the housing of the light collector; the pitch main shaft and the azimuthal main shaft connected to the housing of the light collector are both hollow cylinders having inner walls provided with reflective films, and the optical paths in the hollow cylinders of the pitch main shaft and the azimuthal main shaft communicate with each other; 
Sustav prema zahtjevu 2, naznačen time što uređaj za provođenje svjetlosti je cilindar koji provodi svjetlost koji ima okomito učvršćen prednji kraj; konveksno-konkavna skupina leća povezana s cilindrom za provođenje svjetlosti smještena je u kućištu svjetlosnog kolektora; glavna osovina nagiba i glavna osovina azimuta spojene na kućište svjetlosnog kolektora su obje šuplji cilindri koji imaju unutarnje stjenke opremljene reflektirajućim filmovima, a optičke putanje u šupljim cilindrima glavne osovine nagiba i glavne osovine azimuta su u međusobnoj vezi;
represents linear or branched PEG 20kDa to 80kDa endcapped with a methoxy-group, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation. 
predstavlja ravni ili razgranati PEG 20 kDa do 80 kDa koji kao završnu skupinu ima metoksi-skupinu, ili jedna od njegovih soli, njegovih solvata ili solvata njegovih soli.
an HVR-L3 comprising the amino acid sequence of SEQ ID NO:13, wherein the antibody is a bispecific antibody. 
HVR-L3 koji sadrži aminokiselinsku sekvencu od SEQ ID NO:13; pri čemu po želji slabi lanac obuhvaća:
Example 2: Synthesis of further compounds of the invention 
Datum objave europske prijave patenta:
A suspension device according to claim 3, characterized in that the respective pin (17, 27) is fixedly connected to one of said covering plates (7a, 7b) and arranged to engage with a fixing member (8a, 8b) of the other covering plate, which fixing member is adapted to the pin, in order to secure the covering plates to each other. 
Naprava za vješanje u skladu s patentnim zahtjevom 3, naznačena time, da su dotične igle (17, 27) čvrsto povezane s jednom od navedenih pokrovnih ploča (7a, 7b) i uređene da se povežu s elementom za pričvršćivanje (84, 8b) druge pokrovne ploče, a element za pričvršćivanje prilagođen je igli, kako bi se pokrovne ploče međusobno učvrstile.
Method according to claim 16-19, wherein the composition contains at least 0.1%, preferably at least 0.3%, of a fructosazine selected from the group consisting of 2,5-deoxyfructosazine, 2,6-deoxyfructosazine, 2,5-fructosazine, 2,6-fructosazine and combinations thereof, by weight of dry matter. 
Postupak prema zahtjevu 16-19, naznačen time, što pripravak sadržava najmanje 0,1%, poželjno najmanje 0,3%, fruktozazina odabranog iz skupine koju sačinjavaju 2,5-deoksifruktozazin, 2,6-deoksifruktozazin, 2,5-fruktozazin, 2,6-fruktozazin i njihove kombinacije, po masi suhe tvari.
Process for the manufacture of a nutritional composition according to embodiments 1 to 12 comprising preparing an aqueous phase comprising protein and digestible carbohydrates and preparing a fat phase comprising lipids, wherein phospholipids are present in the aqueous and/or fat phase, wherein the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, wherein the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 15 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, mixing the fat and aqueous phase and homogenizing the mixture of fat and aqueous phase into an oil-in-water emulsion with lipid globules at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
20. Postupak proizvodnje nutritivnog pripravka prema zahtjevima 1 do 13 koji obuhvaća pripremu vodene faze koja sadrži proteine i probavljive ugljikohidrate te pripremu masne faze koja sadrži lipide, gdje su fosfolipidi prisutni u vodenoj i/ili masnoj fazi, gdje sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, gdje sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida, zatim miješanje masne i vodene faze te homogeniziranje smjese masne i vodene faze u emulziju tipa ulje-u-vodi s lipidnim globulama koje su barem djelomično obložene fosfolipidima na
The application of the combositions according to the invention can be for instance once a day, or depending on the duration of action of the anticholinergic agent twice a day, or once every 2 or 3 days. 
Kombinacije sukladno predmetnom izumu mogu se davati jedanput na dan ili, ovisno o trajanju djelovanja antikolinergijskog sredstva, dvaput na dan ili jedanput svaka 2 ili 3 dana, pa čak i "prema potrebi" (u odredenim danima, tri ili više puta na dan).
A process according to any preceding claim wherein step (ii) comprises reacting said compound of formula IIIb with a compound of formula II in the presence of a coupling agent. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak (1i) sastoji u reakciji navedenog spoja formule IIIb sa spojem formule II u prisutnosti kondenzacijskog sredstva.
The glove according to claim 8, wherein said means material is an absorbent, non-woven, mono layer gauze. 
Rukavica u skladu s patentnim zahtjevom 8, naznačena time što je materijal navedenog sredstva apsorbirajuća, netkana, jednoslojna gaza.
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje kad je testiran u komparativnoj kliničkoj studiji je bioekvivalentan trgovačkom proizvodu OxyContin"".
In further embodiments, the hemihydrate has an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at about 13.7°, about 14.9°, about 15.4°, about 15.8°, and about 16.7°. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima uzorak difrakcije praha X-zrakama koji sadrži pikove, u značenju 20, na oko 13.7%, oko14.9%, oko 15.4%, oko 15.8%, oko 16.7, oko 20.1% i oko 21.4".
The method of any one of the preceding claims, wherein the pH during cultivation at the first temperature and/or the second temperature is between 6 and 8. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pH tijekom uzgoja na prvoj temperaturi 1/ili drugoj temperaturi između 6 i 8.
A nucleic acid for use according to claim 1, wherein said polypeptide has at least 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2. 
Polipeptid za uporabu, sukladno zahtjevu 1, naznačen time, da navedeni peptid ima najmanje 90% identičnosti sa SEQ ID NO: Lili SEQ ID NO: 2.
Method according to claim 1, wherein a length of the at least one X-ray pulse corresponds to a life time of a partial discharge. 
Metoda prema jednom od prethodnih zahtjeva, pri čemu duljina najmanje jednog rendgenskog impulsa (7) načelno odgovara vijeku trajanja djelomičnog izboja.
The integrated circuit according to one of claims 1 to 9, wherein in the second allocation, Localized Virtual Resource Blocks, LVRBs, are mapped to PRBs, and the LVRBs are allocated to the mobile station apparatus in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The pharmaceutical composition of either claim 1 or 2, wherein the mammal was previously immunized with Bacillus Calmette-Guerin (BCG). 
Farmaceutski pripravak u skladu s bilo patentnim zahtjevom 1 ili 2, naznačen time što je sisavac prethodno imuniziran cjepivom Bacillus Calmette-Gućrin (BCG).
dose b of tapentadol, preferably once daily (sid), twice daily (bid) or thrice daily (tid), during a second administration interval following the first administration interval, 
Tapentadol prema patentnom zahtjevu 1, naznačen time da se doza a i doza b tapentadola daju jednom dnevno (sid), dvaput dnevno (bid) i triput dnevno (tid).
The process of paragraph 57, wherein Compound 6 is prepared by a process comprising: reacting acrolein with CH3NO2 to produce Compound 8: reacting Compound 8 with Na2S2O5 to produce Compound 9: 
Postupak u skladu s patentnim zahtjevom 47, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u: (a) reakciji akroleina s CHaNO, kako bi se dobilo Spoj 8:
The method according to any preceding claim, wherein water is added to the fluid immiscible with water prior to step b, c, or d and wherein the water may contain the aqueous first and/or second reagents. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se tekućini koja se ne miješa s vodom dodaje voda prije koraka b, c ili d i pri čemu voda može sadržavati prvi i / ili drugi vodeni reagens.
An agricultural composition comprising an association of an at least partially depolymerised chitosan with a bivalent copper chelate; 
Kompozicija za poljoprivredu koja sadrži spoj bar djelomično depolimeriziranog hitozana i dvovalentnog helata bakra;
The method of claim 1, the prodrug compound is represented by a structure of Formula 9 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
Sastav iz patentnog zahtjeva 1, tvar sadrži strukturu Formule 9 ili njen stereoizomer ili njenu farmaceutski prihvatljivu sol.
transducing a compatible host cell with the integration-defective vector of any of the preceding claims comprising in operable combination the nucleotide sequence of interest and one or more site-directed recombination sequences; and 
(a) transdukciju kompatibilne stanice domaćina vektorom manjkavim u integraciji prema bilo kojem od prethodnih patentnih zahtjeva koji sadrži u funkcionalnoj kombinaciji nukleotidnu sekvencu od interesa i jednu ili više sekvenci za upravljanu rekombinaciju;
It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. 
Također traži prekursore koji sadrže funkcionalne skupine koje se mogu reducirati poput aldehida, ketona, laktona i ostera.
Use of a foamable composition essentially free of pharmaceutically active ingredients, according to claim 6 for the medical treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis. 
Uporaba pripravka koji se može pjeniti uglavnom bez farmaceutskih aktivnih sastojaka prema zahtjevu 1, koji sadrži [image] naznačena time da je za proizvodnju lijeka pakiranog u spremnik s ispusnim ventilom za liječenje rosacea ili akni.
10 % or more, the weight of the partial sugar replacement composition being 100 %. 
10 % ili više, pri čemu težina sastavine koja djelomice zamjenjuje šećer iznosi 100 %.
An ink cartridge (3) according to any preceding claim, wherein guide interface comprises a guide track (21), and the guide track (21) has a guide engaging surface that extends parallel to said straight line (Y). 
Uložak za tintu (3) u skladu s patentnim zahtjevom 1, naznačen time što sučelja na prednjoj površini imaju sučelje za poravnavanje izbacivača (36), gdje sučelje za poravnavanje izbacivača (36) ima prstenasti rub.
The machine being discussed here is an electrically powered machine that enables a beverage to be prepared at a rate of a single dose at a time, such as for example a cup of espresso coffee from each capsule. 
Stroj kojeg sc opisuje u ovoj specifikaciji je stroj na električni pogon, što omogućuje da sc napitak pripravi brzinom od po jedne doze, poput primjerice šalice espreso-kave iz svake kapsule.
wherein: said window or door comprises motor means (4) which are mounted to said openable door element level with the drive devices (2) and are operably associated with said drive devices (2) to control actuation of said first engagement means (8) between said engagement and disengagement positions; 
- - prozor ili vrata obuhvaća motorna sredstva (4) postavljena na element vrata koja se mogu otvoriti u razini s pogonskim sredstvima (2) 1 operativno su povezana s tim pogonskim sredstvima (2) radi kontrole funkcije prvih sredstava za zahvaćanje (8) između zahvaćenih i odvojenih položaja;
On the other hand, even if IL-18BP binds to such resin, the conditions recommended to elute antibodies were not expected to work for IL-18BP, since changing the pH from pH7.2 to pH4 does not cause IL-18BP to became positively charged and therefore IL-IBP under such pH conditions is expected to remain bound to the column. 
Sa druge strane čak i ako bi se IL-18BP vezao na takvu smolu, uvjeti preporučeni za eluaciju antitijela ne bi odgovarali za eluaciju IL-18BP, budući da i nakon promjene pH sa pH 7.2 na pH 4, IL-18BP ostaje negativno nabijen te sc pod takvim uvjetima pH očekuje i da će ostati vezan na kolonu.
A compound represented by the formula (2'): wherein R is a fluorine atom or a methoxy group, and R400 is a hydrogen atom or a C1 - C4 alkyl group, or a salt thereof. 
Spoj, naznačen time što je prikazan formulom (2′): [image], gdje je R atom fluora ili skupina metoksi, a R400 je atom vodika ili C1-C4 alkilna skupina, ili njegova sol.
a protective layer (14) and a waterproofing layer (15) for the outer face (18) of said hollow structure (16), 
- zaštitni sloj (14) i vodootporni sloj (15) za vanjski dio (18) navedene šuplje strukture (16),
Add 150 µl of culture medium to all the wells of row A (Control Cells wells). 
Dodaj 150 ul stanične podloge svim jažicama iz reda A (jažice s kontrolnim stanicama).